NCT02933580View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

February 4, 2017

Study Completion Date

February 4, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-56136379

Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.

OTHER

Placebo

Participants will receive matching placebo tablets on Day 1.

Trial Locations (1)

Unknown

Glendale

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02933580 - A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants | Biotech Hunter | Biotech Hunter